Astrazeneca

FromAstraZeneca ([email protected])
Subject (47)Lynparza approved in EU for early breast cancer
Preheader (133)Lynparza approved in the EU as adjuvant treatment for patients with germline BRCA-mutated HER2-negative high-risk early breast cancer
Typography
Arial
Colors
Text Analysis
Body Words228
Subject Words8
Body Emojis1
Subject Emojis
Media Analysis
Text Links8
Image Links4
Total Links12
Images7
Technical Metrics
Performance
HTML Size, Kb
Pixel Length, px788 px
X-Spam Score0.4
Preheader OptimizedNo
Timing
Day of WeekThursday
TimeAfternoon

Lynparza approved in EU for early breast cancer

Lynparza approved in the EU as adjuvant treatment for patients with germline BRCA-mutated HER2-negative high-risk early breast cancer
Lynparza approved in EU for early breast cancer